C. H. Gleiter

10.8k total citations · 1 hit paper
46 papers, 6.3k citations indexed

About

C. H. Gleiter is a scholar working on Molecular Biology, Pharmacology and Hematology. According to data from OpenAlex, C. H. Gleiter has authored 46 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Pharmacology and 8 papers in Hematology. Recurrent topics in C. H. Gleiter's work include Erythropoietin and Anemia Treatment (8 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Pharmaceutical studies and practices (5 papers). C. H. Gleiter is often cited by papers focused on Erythropoietin and Anemia Treatment (8 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Pharmaceutical studies and practices (5 papers). C. H. Gleiter collaborates with scholars based in Germany, Switzerland and United States. C. H. Gleiter's co-authors include Klaus Mörike, Anne Simmenroth-Nayda, M M Kochen, Hartmut Oßwald, Eva Hummers, Wolfgang Himmel, Thomas Ledig, Wilhelm Niebling, Matthias Schwab and Richard Fux and has published in prestigious journals such as CHEST Journal, Cell Death and Differentiation and Psychopharmacology.

In The Last Decade

C. H. Gleiter

46 papers receiving 6.1k citations

Hit Papers

align trajectories

Peers

C. H. Gleiter

MB

PHARM

OC

PHARM

PHYSI

D Pharm United States

Aziz Karim United States

Thomas P. Johnston United States

Michinao Mizugaki Japan

Shizuo Yamada Japan

Laurie Goodman United States

Amnon Hoffman Israel

Yong Liu China

B.K. Matuszewski United States

Elźbieta Skrzydlewska Poland

D Pharm United States

C. H. Gleiter

1.3k ×0.9

MB

903 ×1.1

PHARM

342 ×0.4

OC

444 ×0.7

PHARM

685 ×1.2

PHYSI

Citations per year, relative to C. H. Gleiter C. H. Gleiter (= 1×) peers D Pharm

Countries citing papers authored by C. H. Gleiter

Since Specialization

Citations

This map shows the geographic impact of C. H. Gleiter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. H. Gleiter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. H. Gleiter more than expected).

Fields of papers citing papers by C. H. Gleiter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. H. Gleiter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. H. Gleiter. The network helps show where C. H. Gleiter may publish in the future.

Co-authorship network of co-authors of C. H. Gleiter

This figure shows the co-authorship network connecting the top 25 collaborators of C. H. Gleiter. A scholar is included among the top collaborators of C. H. Gleiter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. H. Gleiter. C. H. Gleiter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Gleiter, C. H., et al.. (2011). Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults. International Journal of Clinical Pharmacology and Therapeutics. 49(7). 451–460. 6 indexed citations

2.

Danielyan, Lusine, Richard Schäfer, Anja Schulz, et al.. (2009). Survival, neuron-like differentiation and functionality of mesenchymal stem cells in neurotoxic environment: the critical role of erythropoietin. Cell Death and Differentiation. 16(12). 1599–1614. 48 indexed citations

3.

Ufer, Mike, Olaf Junge, Gisbert Selke, et al.. (2007). Patterns and prevalence of antidepressant drug use in the German state of Baden‐Wuerttemberg: a prescription‐based analysis. Pharmacoepidemiology and Drug Safety. 16(10). 1153–1160. 29 indexed citations

4.

Fux, Richard, et al.. (2006). Multiple drug prescribing by general practitioners in a German region: implications for drug interactions and patient safety. International Journal of Clinical Pharmacology and Therapeutics. 44(11). 539–547. 10 indexed citations

5.

Grenz, Almut, J Klein, Christoph Köhle, et al.. (2006). Effect of endothelin-1 on erythropoietin production in a rat model under normoxia and functional carbon monoxide-induced hypoxia. Naunyn-Schmiedeberg s Archives of Pharmacology. 373(5). 342–348. 4 indexed citations

6.

Dilger, K., Martin Alberer, Andreas Büsch, et al.. (2006). Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Alimentary Pharmacology & Therapeutics. 23(3). 387–396. 14 indexed citations

7.

Fux, Richard, Klaus Mörike, U. Delabar, et al.. (2005). Impact of genotype on adverse effects during treatment with metoprolol: A prospective clinical study. Clinical Pharmacology & Therapeutics. 78(4). 378–387. 88 indexed citations

8.

Zech, Karl, et al.. (2004). Oral, Once-Daily Roflumilast and Its Active N-oxide Metabolite Exhibit Dose-Proportional Pharmacokinetics Between 250μg and 500μg. CHEST Journal. 126(4). 804S–804S. 1 indexed citations

9.

Freudenthaler, Stefan, Peter Benöhr, Almut Grenz, et al.. (2003). Do alterations of endogenous angiotensin II levels regulate erythropoietin production in humans?. British Journal of Clinical Pharmacology. 56(4). 378–387. 11 indexed citations

10.

Klotz, Ulrich, Winfried Beil, C. H. Gleiter, et al.. (2003). Arzneimittelinteraktionen. Der Internist. 44(11). 1444–1449. 8 indexed citations

11.

Schmidt, Harald, Stefan Viktor Vormfelde, Klaus Klinder, et al.. (2003). The role of active metabolites in dihydrocodeine effects. International Journal of Clinical Pharmacology and Therapeutics. 41(3). 95–106. 30 indexed citations

12.

Meisner, Christoph, et al.. (2002). „Off-label” Verschreibung von Arzneimitteln in der ambulanten Versorgung von Kindern und Jugendlichen. DMW - Deutsche Medizinische Wochenschrift. 127(48). 2551–2557. 22 indexed citations

13.

Brink, Marijke, et al.. (2000). Dose-dependent effect of angiotensin II on human erythropoietin production. Pflügers Archiv - European Journal of Physiology. 439(6). 838–844. 38 indexed citations

14.

Oppert, Michael, C. H. Gleiter, Christian Müller, et al.. (1999). Kinetics and characteristics of an acute phase response following cardiac arrest. Intensive Care Medicine. 25(12). 1386–1394. 14 indexed citations

15.

Gleiter, C. H., et al.. (1997). Erythropoietin production in healthy volunteers subjected to controlled hypobaric hypoxia: further evidence against a role for adenosine. British Journal of Clinical Pharmacology. 44(2). 203–205. 7 indexed citations

16.

Mühlbauer, Bernd, et al.. (1997). Renal response to infusion of dopamine precursors in anaesthetized rats. Naunyn-Schmiedeberg s Archives of Pharmacology. 356(6). 838–845. 12 indexed citations

17.

Gleiter, C. H., Stefan Freudenthaler, U. Delabar, et al.. (1996). Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine. British Journal of Clinical Pharmacology. 42(6). 729–735. 14 indexed citations

18.

Gleiter, C. H., et al.. (1996). Adverse CNS-Effects of Beta-Adrenoceptor Blockers. Pharmacopsychiatry. 29(6). 201–211. 35 indexed citations

19.

Volz, Hans‐Peter, et al.. (1996). Brofaromine ? a review of its pharmacological properties and therapeutic use. Journal of Neural Transmission. 103(1-2). 217–245. 13 indexed citations

20.

Gleiter, C. H., et al.. (1994). Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers. Journal of Neural Transmission. 95(3). 241–245. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact